Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study

Background: The optimal anti-angiogenic strategy as second-line treatment in RAS wild-type metastatic colorectal cancer (mCRC) treated with anti-EGFR (Epidermal Growth Factor Receptor) based first-line treatment is still debated. Methods: This multicenter, real-world, retrospective study is aimed at...

Descripción completa

Detalles Bibliográficos
Autores principales: Parisi, Alessandro, Cortellini, Alessio, Cannita, Katia, Venditti, Olga, Camarda, Floriana, Calegari, Maria Alessandra, Salvatore, Lisa, Tortora, Giampaolo, Rossini, Daniele, Germani, Marco Maria, Boccaccino, Alessandra, Dell’Aquila, Emanuela, Fulgenzi, Claudia, Santini, Daniele, De Tursi, Michele, Tinari, Nicola, Di Marino, Pietro, Lombardi, Pasquale, Roselló Keränen, Susana, Huerta Álvaro, Marisol, Zurlo, Ina Valeria, Corsi, Domenico Cristiano, Emiliani, Alessandra, Zanaletti, Nicoletta, Troiani, Teresa, Vitale, Pasquale, Giampieri, Riccardo, Merloni, Filippo, Occhipinti, Mario Alberto, Marchetti, Paolo, Roberto, Michela, Mazzuca, Federica, Ghidini, Michele, Indini, Alice, Garajova, Ingrid, Zoratto, Federica, Delle Monache, Simona, Porzio, Giampiero, Ficorella, Corrado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281759/
https://www.ncbi.nlm.nih.gov/pubmed/32429380
http://dx.doi.org/10.3390/cancers12051259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281759/
https://www.ncbi.nlm.nih.gov/pubmed/32429380
http://dx.doi.org/10.3390/cancers12051259

Ejemplares similares